TG Therapeutics is a biopharmaceutical company founded to apply scientific advances to the development of treatment options for patients. Its work focuses on discovering and developing therapies for immune-mediated diseases, with a particular emphasis on multiple sclerosis. The company’s marketed product, BRIUMVI (ublituximab), is indicated for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

TG Therapeutics also advances a research and development pipeline that includes subcutaneous ublituximab and azer-cel, alongside ublituximab in its existing form. Its website provides information about the company’s scientific approach, publications, clinical trials, and expanded access policy, as well as safety and prescribing information for BRIUMVI. The company also shares corporate news, investor materials, financial reports, and details about its leadership and guiding principles.

Through its research, clinical development, and commercial activities, TG Therapeutics aims to translate scientific progress into potential and available treatment options for patients and to support continued advancement in multiple sclerosis care